open access

Vol 67, No 3 (2016)
Case report
Published online: 2016-01-27
Submitted: 2015-09-21
Accepted: 2015-12-15
Get Citation

Late liver metastasis of medullary thyroid cancer with low calcitonin levels — successfully cured by radiofrequency

Abdallah Al-Salameh, Camille Baudry, Jean François Gautier, Marie-Elisabeth Toubert, Hélène Bihan, Régis Cohen
DOI: 10.5603/EP.a2016.0038
·
Endokrynologia Polska 2016;67(3):326-329.

open access

Vol 67, No 3 (2016)
Case report
Published online: 2016-01-27
Submitted: 2015-09-21
Accepted: 2015-12-15

Abstract

A 28-year-old female consulted in 1994 for a left thyroid nodule known for two years with documented progression. Left lobe resection was performed initially followed by total thyroidectomy without lymph node dissection in September 1994. Pathological examination concluded on unilateral 10 × 40 mm medullary thyroid carcinoma (MTC). RET mutation was negative. Basal and pentagastrin-stimulated CT levels had been normal from 1994 to 2008 when her CT level was found to be elevated at 33 ng/L and increased subsequently to 111 ng/L in 2010. In accordance with guidelines, cervical ultrasound was performed repeatedly with negative results. After discussion in a multidisciplinary meeting and with patient’s consent, an F-Dopa PET scan was proposed in disagreement with guidelines. This scan showed unique uptake in liver segment VI, which was confirmed by MRI. CT levels reached to 253 ng/L when she finally accepted treatment. In February 2013 we performed radiofrequency ablation of the lesion, which allowed normalisation of CT levels. This observation highlights the possibility of late recurrence of MTC. We could propose that for MTC patients with low-calcitonin levels-recurrences F-DOPA-PET/CT is a good diagnostic tool to use in case of repeatedly negative US neck studies. (Endokrynol Pol 2016; 67 (3): 326–329)

Abstract

A 28-year-old female consulted in 1994 for a left thyroid nodule known for two years with documented progression. Left lobe resection was performed initially followed by total thyroidectomy without lymph node dissection in September 1994. Pathological examination concluded on unilateral 10 × 40 mm medullary thyroid carcinoma (MTC). RET mutation was negative. Basal and pentagastrin-stimulated CT levels had been normal from 1994 to 2008 when her CT level was found to be elevated at 33 ng/L and increased subsequently to 111 ng/L in 2010. In accordance with guidelines, cervical ultrasound was performed repeatedly with negative results. After discussion in a multidisciplinary meeting and with patient’s consent, an F-Dopa PET scan was proposed in disagreement with guidelines. This scan showed unique uptake in liver segment VI, which was confirmed by MRI. CT levels reached to 253 ng/L when she finally accepted treatment. In February 2013 we performed radiofrequency ablation of the lesion, which allowed normalisation of CT levels. This observation highlights the possibility of late recurrence of MTC. We could propose that for MTC patients with low-calcitonin levels-recurrences F-DOPA-PET/CT is a good diagnostic tool to use in case of repeatedly negative US neck studies. (Endokrynol Pol 2016; 67 (3): 326–329)

Get Citation

Keywords

medullary thyroid carcinoma; calcitonin; radiofrequency

About this article
Title

Late liver metastasis of medullary thyroid cancer with low calcitonin levels — successfully cured by radiofrequency

Journal

Endokrynologia Polska

Issue

Vol 67, No 3 (2016)

Pages

326-329

Published online

2016-01-27

DOI

10.5603/EP.a2016.0038

Bibliographic record

Endokrynologia Polska 2016;67(3):326-329.

Keywords

medullary thyroid carcinoma
calcitonin
radiofrequency

Authors

Abdallah Al-Salameh
Camille Baudry
Jean François Gautier
Marie-Elisabeth Toubert
Hélène Bihan
Régis Cohen

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl